AbbVie had promising double-digit growth in Skyrizi/Rinvoq and excellent ex-Humira portfolio sales growth. Read why ABBV ...

October often brings both opportunity and volatility to the stock market. For investors seeking stability and income, ...

Blue Shield of California just negotiated a price of a blockbuster drug that is a quarter of what it pays now. Can it do the ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

It’s the first time this type of model has been used to bring a Humira biosimilar to market, according to the insurer — and ...

Continuous intracerebroventricular administration of a novel dopamine formulation appears safe in Parkinson's disease and may ...

Classic psychedelics, some advocates argue, come with too much baggage. But these altered, “next generation” medications may ...

Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

A major California health insurer is set to offer one of the world’s top-selling drugs for free in a bid to show it can reach ...

At the time, the insurer said it would save as much as $500 million a year by gaining more control over its drug purchasing.